Biotech Values

[DewDiligence]

Enhanced warfarin is still warfarin. The new crop of oral anticoagulants will be better, safer, and much more convenient insofar as they won't requite delicate titration and continual monitoring. The only advantage warfarin will have in the marketplace is that it's cheap, and ARYX's drug won't even have that. All told, I think Tecarfarin is one of the most ill-conceived clinical programs in the biotech industry.